Andrew G. Cole

Andrew G. Cole

Auto-generated profile, based on publicly available information

Andrew G. Cole

Arbutus Biopharma, Inc., 701 Veterans Circle, Warminster, Pennsylvania 18974, United States

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
ACAndrew G Cole
Andrew G Cole

4 September 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ACAndrew G. Cole
Andrew G. Cole
SKSteven G. Kultgen
Steven G. Kultgen
NMNagraj Mani
Nagraj Mani
KFKristi Yi Fan
Kristi Yi Fan
AAAndrzej Ardzinski
Andrzej Ardzinski
MSMichael J. Sofia
Michael J. Sofia

21 February 2024 in Viruses
Verified
Journal Article
Open access
PDF file
ALAngela M Lam
Angela M Lam
RDRavi R Dugyala
Ravi R Dugyala
MSMuhammed Sheraz
Muhammed Sheraz
FLFei Liu
Fei Liu
ETEmily P. Thi
Emily P. Thi
ASAnd Michael J Sofia
And Michael J Sofia
HBV RNA destabilizers are a class of small-molecule compounds that target the noncanonical poly(A) RNA polymerases PAPD5 and PAPD7, resulting in HBV RNA degradation and the suppression of viral proteins including the hepatitis B surface antigen (HBsAg). AB-161 is a next-generation HBV RNA destabilizer with potent antiviral activity, inhibiting HBsAg expressed from cccDNA and integrated HBV DNA in HBV cell-based models. AB-161 exhibits broad HBV genotype coverage, maintains activity against variants resistant to nucleoside analogs, and shows additive effects on HBV replication when combined with other classes of HBV inhibitors. In AAV-HBV-transduced mice, the dose-dependent reduction of HBsAg correlated with concentrations of AB-161 in the liver reaching above its effective concentration mediating 90% inhibition (EC90), compared to concentrations in plasma which were substantially below its EC90, indicating that high liver exposure drives antiviral activities. In preclinical 13-week safety studies, minor non-adverse delays in sensory nerve conductance velocity were noted in the high-dose groups in rats and dogs. However, all nerve conduction metrics remained within physiologically normal ranges, with no neurobehavioral or histopathological findings. Despite the improved neurotoxicity profile, microscopic findings associated with male reproductive toxicity were detected in dogs, which subsequently led to the discontinuation of AB-161’s clinical development.

25 August 2023 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ACAndrew G. Cole
Andrew G. Cole
SKSteven G. Kultgen
Steven G. Kultgen
NMNagraj Mani
Nagraj Mani
JQJorge G. Quintero
Jorge G. Quintero
KFKristi Yi Fan
Kristi Yi Fan
MSMichael J. Sofia
Michael J. Sofia

19 January 2022 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ACAndrew G. Cole
Andrew G. Cole
SKSteven G. Kultgen
Steven G. Kultgen
NMNagraj Mani
Nagraj Mani
AAAndrzej Ardzinski
Andrzej Ardzinski
KFKristi Yi Fan
Kristi Yi Fan
MSMichael J. Sofia
Michael J. Sofia
Disruption of the HBV viral life cycle with small molecules that prevent the encapsidation of pregenomic RNA and viral polymerase through binding to HBV core protein is a clinically validated approach to inhibiting HBV viral replication. Herein we report the further optimisation of clinical candidate AB-506 through core modification with a focus on increasing oral exposure and oral half-life. Maintenance of high levels of anti-HBV cellular potency in conjunction with improvements in pharmacokinetic properties led to multi-log10 reductions in serum HBV DNA following low, once-daily oral dosing for key analogues in a preclinical animal model of HBV replication.